In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
In 2013, 17 new orphan drugs were launched in the US, the highest number of orphan drugs introduced to the US market in more than a decade.
As pharmaceutical companies seek ways to improve R&D productivity and reach commercialization, they are...
Following a decline in 2012, nominal and real-per-capita spending for medicines increased in the US, but growth in spending for medicines in the US remains at historical lows.
The US pharmaceutical market recovered in 2013, posting positive...
Biosimilar developers have to consider evolving manufacturing technologies and capacity issues in their commercialization strategies.
Biosimilars represent a niche but important opportunity in the global biopharmaceutical market. Although the...
Although the US gets high marks for biopharmaceutical R&D and manufacturing activity, its long-term advantage depends of favorable policy to support the industry, concludes a recent report.
A recent analysis by the Pharmaceutical Research and...
An upcoming workshop May 8 and 9, 2014 is the next step in a 10-year implementation plan by FDA to create an electronic, interoperable system to identify and trace prescription drugs as they are distributed in the United States.
Implementation of...
Looking at the first quarter of 2014, there have been several noteworthy deals and activity among contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs).
The key deal thus far in 2014 is the...
Global and US venture-capital funding is up in the first quarter and the number of global and US IPOs increases year over year.
Financing into the global and US biotech sector is an important barometer of the health of that sector and is an...
Procurement is increasingly being asked to drive productivity and generate value. Top executives share their experience on key strategies.
As the pharmaceutical industry faces challenges in improving R&D productivity, augmenting sales, and...
A move to value-based outcomes in drug development, increased penetration of specialty drugs, and the continued rise of emerging markets are key trends shaping the global pharmaceutical market.
The outlook for the global pharmaceutical market is...
Larger social and healthcare issues are playing a greater role in drug development and commercialization strategies.
Pharmaceutical companies have always faced the scientific and technical challenges of new drug development, but they are now also...
